Acute Myeloid Leukemia With FLT3/ITD Mutation
Oncology
Prevalence
6.0 / 100K
Incidence
4.3 / 100K/yr
2 drugs in development·1 company·1 clinical trial
Drug Pipeline by Phase
Phase 3(1)
| Drug | Company |
|---|---|
| Vyxeos | Jazz Pharmaceuticals plc (JAZZ) |
Phase 1(1)
| Drug | Company |
|---|---|
| Gilteritinib | Jazz Pharmaceuticals plc (JAZZ) |
Compare drugs
Frequently asked questions
How many drugs are in development for Acute Myeloid Leukemia With FLT3/ITD Mutation?
BioSniper tracks 2 drugs in development for Acute Myeloid Leukemia With FLT3/ITD Mutation across 1 company.
How many clinical trials target Acute Myeloid Leukemia With FLT3/ITD Mutation?
There are 1 clinical trial targeting Acute Myeloid Leukemia With FLT3/ITD Mutation tracked by BioSniper.
What is the prevalence of Acute Myeloid Leukemia With FLT3/ITD Mutation?
The estimated prevalence of Acute Myeloid Leukemia With FLT3/ITD Mutation is approximately 6.0 per 100,000 population.
Deep-dive into Acute Myeloid Leukemia With FLT3/ITD Mutation
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis